Below analyst target stocks: what the screen found on November 19, 2026
Manufacturing dominates this latest screen, accounting for 29 of the 40 companies that matched the criteria. This concentration suggests the current results are skewed toward a specific sector rather than spread across the broader market…
Key figures
Data as of Nov 19, 2026- ALGS (Aligos Therapeutics, Inc. Common Stock) market cap
- $8.12M
- TVRD (Tvardi Therapeutics, Inc. Common Stock) market cap
- $13.65M
- EYPT (EyePoint, Inc. Common Stock) market cap
- $30.89M
- IBIO (iBio, Inc. Common Stock) market cap
- $56.18M
- CRBP (Corbus Pharmaceuticals Holdings, Inc.) market cap
- $56.87M
- LFMD (LifeMD, Inc. Common Stock) market cap
- $83.13M
Manufacturing dominates this latest screen, accounting for 29 of the 40 companies that matched the criteria¹˒². This concentration suggests the current results are skewed toward a specific sector rather than spread across the broader market of 3,743 companies with available data³.
Every company on this list is trading well under a well-covered consensus target. This gap represents a disconnect between analyst targets and current market prices, but passing this test does not establish that a company is worth owning or that the price will rise. Because analyst targets are rarely revised, a wide gap often reflects a price drop rather than a shift in bullish sentiment.
Among the matching names are several small-cap manufacturing firms that have recently filed quarterly reports and current reports: Aligos Therapeutics, Inc. ($8.12M⁴), Tvardi Therapeutics, Inc. ($13.65M⁵), EyePoint, Inc. ($30.89M⁶), iBio, Inc. ($56.18M⁷), and Corbus Pharmaceuticals Holdings, Inc. ($56.87M). Aligos filed its 10-Q and 8-K on 2026-11-06, while Tvardi did so on 2026-11-13. iBio and Corbus both filed 8-Ks on 2026-11-16.
Also appearing is LifeMD, Inc., a services sector company with a market cap of $83.13M⁸. LifeMD filed a 10-Q and an 8-K covering results, new debt, and a share sale on 2026-11-12.
Educational tool. Not investment advice. This article was produced with automated assistance. Every figure in it was checked against the underlying data before it was published; the interpretation was not.